PFBT
CHRS icon

Parkside Financial Bank & Trust’s Coherus Oncology CHRS Stock Holding History

Parkside Financial Bank & Trust’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-25
Closed -$94 – 2074
2023
Q3 		$94 Sell
25
-245
-91% -$1.13K ﹤0.01% 2031
2023
Q2 		$1.15K Buy
270
+249
+1,186% +$1.47K ﹤0.01% 1814
2023
Q1 		$144 Sell
21
-64
-75% -$497 ﹤0.01% 1975
2022
Q4 		$673 Sell
85
-102
-55% -$785 ﹤0.01% 1876
2022
Q3 		$2K Buy
187
+37
+25% +$374 ﹤0.01% 1512
2022
Q2 		$1K Sell
150
-48
-24% -$417 ﹤0.01% 1687
2022
Q1 		$3K Sell
198
-18
-8% -$229 ﹤0.01% 1468
2021
Q4 		$3K Buy
216
+2
+0.9% +$35 ﹤0.01% 1477
2021
Q3 		$3K Buy
214
+7
+3% +$103 ﹤0.01% 1418
2021
Q2 		$3K Buy
207
+40
+24% +$566 ﹤0.01% 1404
2021
Q1 		$2K Hold
167
– – ﹤0.01% 1472
2020
Q4 		$3K Buy
167
+107
+178% +$1.91K ﹤0.01% 1278
2020
Q3 		$1K Buy
+60
New +$1.12K ﹤0.01% 1301

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parkside Financial Bank & Trust's CHRS Position: Q4 2023 in Review

Parkside Financial Bank & Trust sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 25 shares — an estimated $94 sold.

Parkside Financial Bank & Trust first reported a position in CHRS in Q3 2020 and held it in 13 quarters. The position peaked at $3K in Q1 2022. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

  • Parkside Financial Bank & Trust reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
  • Parkside Financial Bank & Trust sold 25 Coherus Oncology shares in Q4 2023, an estimated $94.
  • Parkside Financial Bank & Trust first reported a position in Coherus Oncology in Q3 2020 and held it in 13 quarters.
  • Parkside Financial Bank & Trust's Coherus Oncology position peaked at $3K in Q1 2022.
  • 156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on Parkside Financial Bank & Trust's 13F filing for Q4 2023, filed 1 Feb 2024.